UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research

Journal of the European Academy of Dermatology and Venereology, 2023-06, Vol.37 (6), p.1168-1174

2023

Volltextzugriff (PDF)

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.733-742

2019

Volltextzugriff (PDF)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.1348-1358

2020

Volltextzugriff (PDF)

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

British journal of dermatology (1951), 2019-07, Vol.181 (1), p.88-95

2019

Volltextzugriff (PDF)

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial

Journal of the European Academy of Dermatology and Venereology, 2021-07, Vol.35 (7), p.1543-1552

2021

Volltextzugriff (PDF)

An indirect comparison of long‐term efficacy of every‐2‐week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12

British journal of dermatology (1951), 2020-07, Vol.183 (1), p.52-59

2020

Volltextzugriff (PDF)

Kindler syndrome: a focal adhesion genodermatosis

British journal of dermatology (1951), 2009-02, Vol.160 (2), p.233-242

2009

Volltextzugriff (PDF)

Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond

Journal of the European Academy of Dermatology and Venereology, 2021-04, Vol.35 (4), p.797-806

2021

Volltextzugriff (PDF)

Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial

Journal of the European Academy of Dermatology and Venereology, 2012-12, Vol.26 (12), p.1516-1521

2012

Volltextzugriff (PDF)

A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis

Journal of the European Academy of Dermatology and Venereology, 2018-01, Vol.32 (1), p.145-151

2018

Volltextzugriff (PDF)

A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.e193-e193

2020

Volltextzugriff (PDF)

生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.e205-e205

2020

Volltextzugriff (PDF)

ASN002 证明有疗效并可改善AD 炎症

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.e113-e113

2019

Volltextzugriff (PDF)

Amélioration du score PASI absolu chez des patients atteints de psoriasis traités par le guselkumab ou le sécukinumab: résultats de l’étude ECLIPSE

Annales de dermatologie et de vénéréologie, 2019-12, Vol.146 (12), p.A70-A71

2019

Volltextzugriff (PDF)

Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab

Journal of the European Academy of Dermatology and Venereology, 2015-08, Vol.29 (8), p.1576-1581

2015

Volltextzugriff (PDF)

Kindler syndrome: a focal adhesion genodermatosis

British journal of dermatology (1951), 2009-02, Vol.160 (2), p.233-242

2009

Volltextzugriff (PDF)

Changes in serum free testosterone, sleep patterns, and 5-alpha-reductase type I activity influence changes in sebum excretion in female subjects

Skin research and technology, 2015-02, Vol.21 (1), p.47-53

2015

Volltextzugriff (PDF)

SA56 Canadian Expert Consensus on Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis

Value in health, 2023-06, Vol.26 (6), p.S407-S407

2023

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Volltextzugriff (PDF)

LB1143 New insights into the role of T cells in psoriasis: Identification of multi-cytokine producing T cell subsets and a skewed relative contribution of IL17A production by tissue resident CD103+CD8+ T cells

Journal of investigative dermatology, 2019-09, Vol.139 (9), p.B25-B25

2019

Volltextzugriff (PDF)

Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris

Journal of cosmetic dermatology, 2009-03, Vol.8 (1), p.19-23

2009

Volltextzugriff (PDF)

Etanercept in the treatment of palmoplantar pustulosis

Journal of drugs in dermatology, 2008-10, Vol.7 (10), p.940

2008

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1675-1684

2008

Volltextzugriff (PDF)

Disseminated linear calcinosis cutis associated with the Koebner phenomenon in an infant with congenital acute monocytic leukaemia

British journal of dermatology (1951), 2004-04, Vol.150 (4), p.753-756

2004

Volltextzugriff (PDF)

生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究

British journal of dermatology (1951), 2020-06, Vol.182 (6)

2020

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(55)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial

An indirect comparison of long‐term efficacy of every‐2‐week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12

Kindler syndrome: a focal adhesion genodermatosis

Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond

Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial

A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis

A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis

生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究

ASN002 证明有疗效并可改善AD 炎症

Amélioration du score PASI absolu chez des patients atteints de psoriasis traités par le guselkumab ou le sécukinumab: résultats de l’étude ECLIPSE

Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab

Kindler syndrome: a focal adhesion genodermatosis

Changes in serum free testosterone, sleep patterns, and 5-alpha-reductase type I activity influence changes in sebum excretion in female subjects

SA56 Canadian Expert Consensus on Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

LB1143 New insights into the role of T cells in psoriasis: Identification of multi-cytokine producing T cell subsets and a skewed relative contribution of IL17A production by tissue resident CD103+CD8+ T cells

Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris

Etanercept in the treatment of palmoplantar pustulosis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Disseminated linear calcinosis cutis associated with the Koebner phenomenon in an infant with congenital acute monocytic leukaemia

生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究

Suchergebnisse filtern